AstraZeneca wins prestigious business development award
Wednesday, 12 September 2012
AstraZeneca won the award for Best Pharma BD&L Team at the Oxford Bioscience Network’s Annual Awards Dinner last night at The Ashmolean Museum, Oxford.
Shaun Grady, VP of Strategic Partnering and Business Development (SPBD), who received the award on behalf of AstraZeneca, said:
It is really pleasing that AstraZeneca has been recognised for our deal making achievements. It has been a busy year and I believe that we have demonstrated that we can be creative in the types of deals we are able to structure. For example, in our collaborations with peer pharma to share capabilities and risk in order to make compelling acquisitions, such as the recent BMS-Amylin deal and previously the acquisition of Novexel with Forest, both of which were called out by the judging panel.
The Best Pharma BD&L team was a new Award at the 2012 event which was Presented by World Courier.
NOTES TO EDITORS
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
OBN is a not-for-profit business network which provides comprehensive support for its member biotech and medtech companies in the South-East England biocluster and the rest of the UK. OBN’s activities can be summarised as networking, partnering, group purchasing, and fundraising advice. Through its delivery of Europe's fastest growing biopartnering and investment conference, BioTrinity, OBN generates more R&D-company-to-investor interactions than anyone else in Europe. OBN is sponsored by Shire, as Corporate Patron, and Corporate Sponsors MEPC, Manches LLP, James Cowper, World Courier, Ernst & Young,Interea, Ardington Archives, SRG, georgejames, FOCUS Insurance and Citigate Dewe Rogerson as well as by its extensive membership of R&D companies and associated industry companies across the entire life sciences industry ecosystem.
AstraZeneca Media Enquiries
Katja Toon +44 20 7604 8268
Oxford Bioscience Network
Andy Smith, Director of Public and Investor Relations
Tel: +44 (0)845 5049 715